rs7679916 — SLC2A9

SLC2A9 Upstream Regulatory Variant rs7679916 — An Emerging Signal for Uric Acid Regulation

Your kidneys filter roughly 700 mg of uric acid per day, reabsorbing most of it through transporters in the proximal tubule before it reaches the urine. The SLC2A9 gene encodes GLUT9¹¹ GLUT9
Glucose Transporter 9, the primary high-capacity urate transporter on the basolateral membrane of proximal tubule cells; it mediates voltage-driven efflux of urate from tubular cells back into the bloodstream, and genetic variation across its approximately 46 kb genomic region accounts for 3–8% of serum urate variance in the population.

rs7679916 lies approximately 2 kilobases upstream of the SLC2A9 transcription start site — in the presumptive promoter region rather than within the gene's coding or intronic sequences. This positions it as a potential regulatory variant affecting how much GLUT9 protein the kidney produces, though the functional mechanism has not been directly demonstrated for this specific variant. It forms part of a high-LD haplotype block (r² > 0.9 among five nearby SNPs) in the upstream region, suggesting these variants are co-inherited and likely tag the same biological signal (Li et al., 2012)²² (Li et al., 2012).

The Mechanism

Because rs7679916 sits upstream of the SLC2A9 coding sequence, it is thought to influence urate handling through transcriptional regulation rather than by changing the GLUT9 protein structure. Variants in presumptive promoter regions can alter transcription factor binding sites: for example, a neighbouring upstream SNP (rs13124007) was found to disrupt a binding site for interferon regulatory factor 1 (IRF-1), potentially reducing SLC2A9 expression. If rs7679916 similarly affects a regulatory element, the T allele may lead to higher GLUT9 expression or activity — increasing urate reabsorption from tubular fluid and raising steady-state serum uric acid levels. However, this mechanistic model is inferred from the genomic context and has not been confirmed by reporter assays or expression quantitative trait locus (eQTL) studies for this specific variant.

The SLC2A9 locus as a whole harbours multiple independent genetic signals for urate levels. rs7679916 represents a potential additional layer to the well-characterised coding signals (rs3733591 Arg265His, rs16890979 Val282Ile) and intronic signals (rs11942223), though whether it is truly independent or in partial LD with these established variants has not been formally tested.

The Evidence

Evidence for rs7679916 specifically is limited. A candidate-gene study of 1,053 hyperuricemia cases and 1,373 normouricemia controls in a Uygur population from Xinjiang, China examined five SLC2A9 SNPs in the upstream region. In the normouricemia subgroup, rs7679916 showed a marginal positive association with serum uric acid concentration (β = 5.77 ± 3.09 mg/dL per allele, P = 0.0626), and the companion upstream variant rs938557 reached significance (β = 11.39, P = 0.0024). Crucially, neither variant showed significant association with hyperuricemia status itself after controlling for age, gender, and BMI (Li et al., 2019)³³ (Li et al., 2019).

The broader promoter-region architecture was characterised by Li et al. (2012), who sequenced 21 SNPs in the ~2 kb upstream region in a Chinese male population and identified two SNPs (rs13124007 and rs6850166) significantly associated with gout (ORs of 1.71 and 1.65 respectively) — but rs7679916 itself was not among the significant hits in that study; it was in high LD with several nearby upstream variants (Li et al., 2012)⁴⁴ (Li et al., 2012).

This evidence base places rs7679916 at an emerging level: a biologically plausible position in the known SLC2A9 regulatory region, marginal association in one population, and no independent replication at the specific variant level.

Practical Actions

SLC2A9 variants as a class — including rs7679916 — point to the same management approach: reducing the purine and fructose inputs that generate uric acid, and supporting the renal machinery that clears it. The key dietary levers with evidence specific to GLUT9 function are:

Purines: Organ meats, shellfish, anchovies, and red meat are the highest-density purine sources. Purine-rich vegetables (spinach, mushrooms, asparagus) have a weaker effect on serum urate than animal purines and are not restricted in major guidelines.

Fructose: High-fructose corn syrup and concentrated fruit juice drive urate synthesis hepatically by depleting ATP and generating AMP, independent of renal transport. SLC2A9-mediated urate transport is facilitated by glucose and fructose — high sugar exposure can amplify urate load on the transporter.

Vitamin C: Vitamin C competitively inhibits urate reabsorption at the renal proximal tubule, providing a genotype-independent uricosuric effect at doses of 200–500 mg/day.

If serum uric acid is borderline or elevated, periodic measurement (every 1–2 years) allows tracking against the clinical threshold of 6.8 mg/dL, above which urate crystallises in joints and soft tissue.

Interactions

With rs11942223 (SLC2A9 intronic signal): rs11942223 is the best-characterised intronic signal at the SLC2A9 locus, explaining up to 6% of urate variance in women. It operates through a regulatory mechanism similar to what rs7679916 may represent. Whether these two upstream/intronic signals are in LD or independent has not been formally assessed — they may partially tag the same haplotype or represent distinct regulatory elements. Carrying risk alleles at both loci would plausibly compound the effect on GLUT9 expression and renal urate clearance.

With rs3733591 (SLC2A9 Arg265His) and rs16890979 (Val282Ile): These coding variants change the GLUT9 protein structure and thus the transporter's intrinsic urate-transport capacity. The upstream variant rs7679916 may act orthogonally — influencing how much transporter is produced rather than how efficiently it functions. Combined effects across regulatory and coding variants at SLC2A9 are additive in their impact on renal urate handling.

With ABCG2 rs2231142 (Q141K): ABCG2 controls intestinal urate secretion (gut efflux pathway). Any renal pathway variant including rs7679916 acts independently of ABCG2. Individuals carrying risk alleles at both rs7679916 and ABCG2 rs2231142 face elevated urate from both the renal reabsorption and intestinal secretion axes simultaneously.